Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clinuvel Pharmaceuticals Limited has announced amendments to its Phase III vitiligo study, offering an extended treatment with SCENESSE® to patients previously on monotherapy and relaxing inclusion criteria to improve patient retention and study completion. These strategic protocol changes aim to enhance recruitment for the study, which is now set to conclude patient enrollment by June 30, 2025, while maintaining the core primary and secondary endpoints. Furthermore, the company has restructured its Clinical Affairs team to better manage larger, global clinical programs.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.